L3VLUP
ProSign in

DYN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DYNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DYN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterDYNJNJ
Q3 20203 holders, $11m30 holders, $26.2bn
Q4 20201 holders, $10m32 holders, $26.6bn
Q1 20211 holders, $5.9m31 holders, $25.3bn
Q2 20212 holders, $19m37 holders, $25.6bn
Q3 20212 holders, $17m40 holders, $24.1bn
Q4 20212 holders, $21m33 holders, $25.2bn
Q1 20222 holders, $26m35 holders, $28.2bn
Q2 20221 holders, $4.6m33 holders, $26.9bn
Q3 20221 holders, $19m36 holders, $25.4bn
Q4 20222 holders, $17m35 holders, $27.6bn
Q1 20231 holders, $432k42 holders, $24.5bn
Q2 20231 holders, $4.3m38 holders, $25.0bn
Q3 20231 holders, $3.0m37 holders, $18.9bn
Q4 20231 holders, $5.8m31 holders, $19.0bn
Q1 20244 holders, $123m32 holders, $19.7bn
Q2 20245 holders, $433m35 holders, $20.4bn
Q3 20245 holders, $392m28 holders, $22.3bn
Q4 20246 holders, $287m37 holders, $20.4bn
Q1 20255 holders, $141m32 holders, $20.5bn
Q2 20253 holders, $94m31 holders, $18.4bn
Q3 20255 holders, $228m32 holders, $23.7bn
Q4 20255 holders, $291m29 holders, $27.8bn
Q1 20265 holders, $264m34 holders, $35.6bn
Q2 20263 holders, $288m33 holders, $39.1bn
DYN

Dyne Therapeutics Inc

Holders
5
Reported value
$141m
Buyers
4
Sellers
2

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$20.5bn
Buyers
16
Sellers
15

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DYN (3)

Farallon Capital Management LLC, PDT Partners LLC, Voloridge Investment Management LLC

Only JNJ (30)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →